Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (November 2023)
30 slides from Little Green Pharma's investor presentation, Nov 20, 2023
Slide 1: Demerger & Capital Raising Investor Presentation
DEMERGER & CAPITAL RAISING INVESTOR PRESENTATION NOVEMBER 2023
Slide 2: Disclaimer
DISCLAIMER Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and This document does not constitute financial product advice or take into account your investment objectives, taxation its activities current as
Slide 3: Overview
EIN ORT rrhwoowr MIND SCIENCES
Slide 4: Key historical figures of the western world
Key historical figures of the western world Dr Albert Hofman Synthesized LSD in labs of Novartis predecessor Self-administered first “trip” in 1943 Isolated psilocybin Timothy Leary Psychologist, former Harvard psychedelics researcher “Turn on, tune in, drop out” “The most dangerous man
Slide 5: Key historical figures of the western world
KEY HISTORICAL FIGURES OF THE WESTERN WORLD “The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to a
Slide 6: The Psychedelic Renaissance
THE PSYCHEDELIC RENAISSANCE Prohibition as part of the “War on Drugs” Number of Academic Publications LSD Psilocybin 6
Slide 7: The Psychedelic Renaissance: Dependence Potential
THE PSYCHEDELIC RENAISSANCE Active/Lethal Dose Ratio and Dependence Potential of Psychoactive Drugs Heroin Very High High Nicotine Morphine Dependence Potential Moderate / Pentobarbital Cocaine High Ephedra Rohypnol Alcohol Moderate LEGEND Narcotics Marijuana Nitrous oxide Caffeine MDMA Moderate / D
Slide 8: The Psychedelic Renaissance
THE PSYCHEDELIC RENAISSANCE Notable active research institutions and NFPs globally: 8
Slide 9: Australia's Mental Health Crisis
MARKET OVERVIEW AUSTRALIA’S MENTAL HEALTH CRISIS Mental health is the most common chronic condition in Australia - ABS figures 2017/18 4.8m (20.1%) Australians had a mental or behavioural condition 3.2m (13.1%) Australians had an anxiety related condition Covid pandemic intensified these issue
Slide 10: Psilocybin & Treatment-Resistant Depression
MARKET OVERVIEW PSILOCYBIN & TREATMENT- RESISTANT DEPRESSION The mental health crisis is exacerbated by a series of treatment-resistant conditions In 2018, a “breakthrough designation” was issued by the US FDA for the treatment of treatment-resistant depression using psilocybin Breakthrough de
Slide 11: TGA Ruling
MARKET OVERVIEW TGA RULING Reset is uniquely positioned to capitalise on the TGA ruling in early 2023 to reclassify psilocybin and MDMA allowing their prescription by authorised psychiatrists under strictly defined parameters from 1 July 2023 Australia is the first country to allow psychiatrists
Slide 12: Other Key Participants
MARKET OVERVIEW OTHER KEY PARTICIPANTS Clinical drug development and Clinical drug development healthcare delivery company and healthcare delivery focused on MDMA company focused on MDMA Joint venture with Canadian Not-for-profit focused on company PharmAla Biotech for the education and advocacy of
Slide 13: Introducing Reset
Reset has been at the forefront of the development of the psychedelics industry in Australia. Our four pillars are: RESET OVERVIEW INTRODUCING RESET Reset incorporated as a 100% subsidiary of Little Green Pharma 1. MENTAL HEALTHCARE PROVIDER 2. CLINICAL TRIAL (LGP) in May 2021 One of the first cli
Slide 14: Our Team
RESET OVERVIEW OUR TEAM Hon. Cheryl Edwards Angus Caithness Shaun Duffy Dr Leon Warne Chairperson & Independent Executive Director Non-Executive Director Chief Operating Officer Non-Executive Director Highly credentialled, experienced Executive director of LGP and an Founding CEO of Reset and a Form
Slide 15: Clinical Advisory Board
RESET OVERVIEW CLINICAL ADVISORY BOARD Dr. Stephen Bright Renee Harvey Clinical Psychologist Clinical Psychologist Co-Founder/VP PRISM Imperial College London MDMA/PTSD trial therapy team. ECU Senior Lecturer
Slide 16: 1. Mental Healthcare Provider
RESET’S FOUR PILLARS 1. MENTAL HEALTHCARE PROVIDER Long-term lease secured for Reset mental health clinic in prime Perth medical precinct Site renovations to complete in November 2023 with HIF contributing $250,000 towards fit-out Reset has secured pharmaceutical psilocybin to supply clinical
Slide 17: HIF Alliance
RESET’S FOUR PILLARS HIF ALLIANCE Reset has entered a strategic alliance with private health insurer Health Insurance Fund of Australia Pty Ltd (HIF) to develop: Proof-of-concept health clinic with HIF funding $250,000 in fit- out costs Health economics study future specialist clinics under ex
Slide 18: 2. WA's First Psilocybin Trial
RESET’S FOUR PILLARS 2. WA’S FIRST PSILOCYBIN TRIAL Clinical trial using psilocybin assisted psychotherapy for treatment resistant depression, with one of Australia’s most respected psychiatrists Prof. Sean Hood as Principal Investigator, and Reset Advisory Board member Dr. Stephen Bright leading
Slide 19: 3. Cultivation
RESET’S FOUR PILLARS 3. CULTIVATION Reset leveraging LGP’s licensed infrastructure, as well as its experience and expertise in production of botanical drug products Purpose-built mushroom cultivation facility co-located at LGP’s existing Schedule 9 licensed cannabis cultivation site in Western A
Slide 20: 4. Manufacture
RESET’S FOUR PILLARS 4. MANUFACTURE Reset progressing GMP licence to manufacture psilocybin for human consumption within manufacturing facilities co-located with Reset’s mental health clinic Separate agreement with LGP granting exclusive access to LGP’s GMP manufacturing facilities for psilocybi
Slide 21: At the Forefront of Australia's Psychedelics Industry
RESET MIND SCIENCES AT THE FOREFRONT OF AUSTRALIA’S PSYCHEDELICS INDUSTRY Mental health clinic GMP psilocybin Clinical trial developed over open to patients in already imported two years commencing Q1 CY2024 Q4 CY2023 for clinical trial and clinic use Psilocybin mushrooms Access to two GMP Only comp
Slide 22: Demerger & Capital Raising
DEMERGER & CAPITAL RAISING 22
Slide 23: Rationale
DEMERGER & CAPITAL RAISING RATIONALE Reset expected to be demerged from the LGP Group by end of CY2023 Demerger comprises an in-specie distribution to existing LGP shareholders together with a capital raise of $2 million on demerger Reset to have pre-money valuation of $2 million on exit, with t
Slide 24: The Offers
DEMERGER & CAPITAL RAISING THE OFFERS Reset proposes to raise $2 million (before costs) by the issue of up to 10 million ordinary shares in Reset at $0.20 per share Offers to consist of: I. Priority offer to Eligible LGP Shareholders of up to 5 million shares at $0.20 per Share to raise up to $1 m
Slide 25: How to Apply
DEMERGER & CAPITAL RAISING HOW TO APPLY Priority Offer Public Offer To apply, you will need to complete and submit a To apply, you should follow the instructions on Priority Offer Application Form the Public Offer Application Form: To access and complete the form, enter your postcode https://a
Slide 26: Indicative Timetable & Key Offer Details
DEMERGER & CAPITAL RAISING INDICATIVE TIMETABLE & KEY OFFER DETAILS Lodgement of Prospectus with ASIC 9 November 2023 Shares on issue at Prospectus Date 100 Priority Offer Record Date 9 November 2023 Shares to be distributed under the In-specie 10,000,000 Distribution Opening Date for the Offers 17
Slide 27: Reset's Investment Opportunity
RESET’S INVESTMENT OPPORTUNITY “We believe Reset Mind Sciences is ideally placed to play a leading role in the evolution of the mental health industry in Australia. Our first mover status has allowed us to attract the highest quality organisations and individuals as potential partners.” — SHAUN DUFF
Slide 28: Thanks for Your Time
THANKS FOR YOUR TIME For further information / FAQs, please refer to the LGP investor website and Reset Mind Sciences website: https://investlittlegreenpharma.com/site/investor- centre/investor-welcome https://www.resetmind.com.au/ website: MORE ABOUT US Registered & Principal Office 13A Bedbrook Pl
Slide 29: Priority Offer
APPENDIX PRIORITY OFFER Priority offer to Eligible LGP Shareholders of up to 5 million Shares at an issue price of $0.20 per Share to raise up to $1 million (before costs) Only LGP Shareholders as at 5:00pm (WST) on 9 November 2023 and located in Australia, or subject to certain restrictions as
Slide 30: Public Offer
APPENDIX PUBLIC OFFER Offer to the general public in Australia and select investors in the United Kingdom and Switzerland of up to 2 million Shares to raise up to $500,000 (before costs) The Company reserves the right to accept oversubscriptions under the Public Offer of up to $1 million Any S
Little Green Pharma — Investor Presentation (November 2023) on 6ix